Impairment of intangible assets totaled $nil in fiscal 2008 and $1,332,000 in fiscal 2007. The Company believed future cash flows may not exceed the carrying value of its biochip technology and in fiscal 2007 recorded an impairment of its biochip technology.
Income tax expenses totaled $153,000 in fiscal 2008 and $105,000 in fiscal 2007. Income taxes are attributable to the Company's operations in Europe where royalty revenue remained flat on a year over year basis.
Liquidity and Capital Resources
Since inception, the Company has financed its operations from public and private sales of equity, the exercise of warrants and stock options, and, to a lesser extent, on interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs.
At July 31, 2008, 2007 and 2006, the Company had cash and cash
equivalents totaling $19,057,000, $11,379,000 and $4,392,000 respectively.
The increase in cash and cash equivalents is the result of several rounds
of private placements. In fiscal 2007, the Company completed a private
placement issuing 3,650,000 units at $1.93 per unit, for gross proceeds of
$7,044,500. Each unit consisted of one common share and one common share
purchase warrant. The common share purchase warrants expired, unexercised
on March 31, 2008. In fiscal 2008, the Company completed another private
placement issuing 10,040,000 common shares at $1.68 per common sha
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved